{"eu_number": "EU-1-21-1541", "parse_date": "2022-11-23 17:10:10.115873", "decisions": [{"filename": "EU-1-21-1541_h_a_dec_0.pdf", "eu_aut_date": "2022-03-24 00:00:00", "eu_brand_name_initial": "Dasatinib Accordpharma", "active_substance": "dasatinib", "eu_nas": false, "eu_atmp": false, "eu_od_initial": "OD Not Found", "eu_mah_initial": "Accord Healthcare S.L.U.", "eu_aut_type_initial": "CMA Not Found", "status": "Parsed"}], "annexes": [{"pdf_file": "EU-1-21-1541_h_a_anx_0.pdf", "xml_file": "EU-1-21-1541_h_a_anx_0.xml", "is_initial": true, "creation_date": "D:20220222113610+05'30'", "modification_date": "D:20220222114537+05'30'", "initial_type_of_eu_authorization": "standard", "eu_type_of_medicine": "small molecule", "therapeutic_indications": "dasatinib accordpharma is indicated for the treatment of adult patients with: \uf0a7 newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. \n \uf0a7 chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib. \n \uf0a7 ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.\n\n dasatinib accordpharma is indicated for the treatment of paediatric patients with: \n \uf0a7 newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib. \n \uf0a7 newly diagnosed ph+ all in combination with chemotherapy.\n"}], "epars": [{"filename": "EU-1-21-1541_h_a_public-assessment-report", "ema_procedure_start_initial": "3/06/2019", "chmp_opinion_date": "27/01/2022", "eu_legal_basis": ["article 10.1"], "eu_prime_initial": "no", "ema_rapp": "john joseph borg", "ema_corapp": "no_co-rapporteur", "ema_reexamination": "no", "eu_accel_assess_g": "no"}], "omars": []}